HISUN(SH:600267) Shen Zhen Shang Bao·2025-11-20 03:51Core Insights - Company Hai Zheng Pharmaceutical is entering the pet food market after expanding into the medical beauty sector, indicating a strategic diversification of its business operations [1][2] - The company plans to invest 200 million yuan in a pet prescription food project, with an expected annual production capacity of 10,000 tons upon completion [1][2] - Hai Zheng Pharmaceutical has faced declining revenues over the past three years, with a revenue drop of 0.82%, 13.82%, and 5.65% from 2022 to 2024 [1] Group 1 - The company approved the establishment of a wholly-owned subsidiary for pet food production, utilizing 100 million yuan of its own funds [1] - The project will be implemented in two phases, with the first phase taking 24 months for construction [1] - The pet food market in China is experiencing significant growth, with a production growth rate of 9.3% and over 500 companies in the sector [2] Group 2 - Hai Zheng Pharmaceutical's revenue for the first three quarters of 2025 was 7.923 billion yuan, a year-on-year increase of 0.61%, while net profit decreased by 10.55% [2] - The company is leveraging its resources in the pet pharmaceutical sector to expand into pet nutrition and health [2] - Hai Zheng Pharmaceutical's animal medicine segment is a key focus, with multiple products achieving significant sales milestones [2][3]